Swissmedic authorises new drug for respiratory disease
The step was taken “after careful consideration”, Swissmedic said on Thursday
Keystone / Peter Schneider
Swiss drugs regulator Swissmedic has authorised a new medicine to treat colds and cases of acute bronchitis in infants and young children. Beyfortus is used to treat respiratory tract diseases caused by the respiratory syncytial virus (RSV).
This content was published on
3 minutes
Keystone-SDA
The step was taken “after careful consideration”, Swissmedic said on Thursday. It is an important step towards prophylaxis against RS viruses, a common cause of respiratory diseases, a Swissmedic spokesperson told the Swiss News Agency Keystone-SDA.
Paediatricians and children’s hospitals in particular have been waiting for the approval. According to the Swiss government, RSV infections in small children in Switzerland lead to around 1,000 hospital admissions per year.
Beyfortus from the pharmaceutical company Sanofi-Aventis is used as a prophylaxis; it is not a vaccine in the conventional sense. The drug is administered intramuscularly as a single injection. Beyfortus is the second such drug against RS viruses. The product Synagis has been authorised in Switzerland since 1999.
RS viruses are common pathogens worldwide and cause many colds in autumn and winter. In newborns and infants, they can lead to pneumonia and hospitalisation.
However, they can also cause severe respiratory illnesses and become dangerous in older people and those with weakened immune systems. According to the British pharmaceutical company GSK, the virus causes more than 270,000 hospital admissions and around 20,000 deaths during hospitalisation in people aged 60 and over in Europe every year.
Catch-up effect after pandemic
After the Covid pandemic subsided, severe respiratory diseases increased significantly again in many countries around the world. Some paediatric clinics were overrun with patients. Experts suspect that this is due to a catch-up effect after the pandemic, when comparatively few children came into contact with RSV.
The disease can currently only be treated symptomatically. An RSV infection does not leave any lasting immunity. The virus can therefore re-infect people of any age.
No vaccine against RSV is available in Switzerland. The EU Commission authorised the vaccine Arexvy in the summer, and the US did the same before that. Vaccines against the RS virus had been sought for years. Experts believe that they could generate billions in sales over the next ten years.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Workplace Switzerland
Trump tariff shock: how Switzerland is positioning itself
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
An atomic ‘tick-tock’ with Swiss technology heads to space to test the Einstein effect
This content was published on
On Monday, the European Space Agency (ESA) launched the ACES set of atomic clocks to measure the effect of gravity on the passage of time.
Swiss Guard swearing-in ceremony postponed following Pope Francis death
This content was published on
The swearing-in ceremony of the Pontifical Swiss Guard, which usually takes place on May 6 each year, has been postponed to a date to be announced next autumn.
Swiss medical device maker Ypsomed to sell diabetes business
This content was published on
Bern-based injection device manufacturer Ypsomed announced on Tuesday that it was selling its diabetes-related activities.
Award-winning Swiss author and scholar Peter von Matt dies aged 87
This content was published on
The Alemannic writer and former professor of German literature Peter von Matt died on Monday in Zurich at the age of 87, following a long illness.
Swiss foreign minister spoke with Iranian counterpart about US dialogue
This content was published on
Swiss Foreign Minister Ignazio Cassis has spoken with his Iranian counterpart Abbas Araghchi about the current dialogue between the US and Iran.
Swiss foreign minister appeals for cohesion and dialogue at Expo in Japan
This content was published on
Swiss Foreign Minister Ignazio Cassis called for cohesion and dialogue at the opening of the Swiss National Day at Expo 2025 in Osaka, Japan, on Tuesday.
Switzerland postpones launch of emergency number for domestic violence victims
This content was published on
The launch of the “142” emergency number, which aims to help victims of domestic violence in Switzerland, has been postponed to May 2026.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.